Brands: Afinitor · Torpenz · Yulithira · Zortress · Everolimus
Average across 39 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Biocon Pharma Inc, | unknown | 20 | SUPPLYING |
| Natco Pharma Limited | unknown | 16 | SUPPLYING |
| Novugen Pharma (USA) LLC | unknown | 12 | SUPPLYING |
| Ascend Laboratories, LLC | generic | 8 | SUPPLYING |
| Breckenridge Pharmaceutical, Inc. | unknown | 8 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | generic | 8 | SUPPLYING |
| Upsher-Smith Laboratories, LLC | unknown | 8 | SUPPLYING |
| Novartis Pharmaceuticals Corporation | unknown | 8 | SUPPLYING |
| Par Health USA, LLC | unknown | 7 | SUPPLYING |
| Aurobindo Pharma Limited | generic | 4 | SUPPLYING |
| CivicaScript LLC | unknown | 4 | SUPPLYING |
| NorthStar RxLLC | relabeler | 4 | SUPPLYING |
| Teva Pharmaceuticals USA, Inc. | generic | 4 | EXITED 2026 |
Shortages, recalls, and registration changes attached to this drug concept.
Everolimus Tablet — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Transplant.
Everolimus Tablet — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Transplant.
Everolimus Tablet — reported in shortage by Endo Pharmaceuticals, Inc.. Therapeutic category: Transplant.
Everolimus Tablet — reported in shortage by Endo Pharmaceuticals, Inc.. Therapeutic category: Transplant.
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Recalling firm: Endo USA, Inc. — Nationwide within the United States
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Recalling firm: Endo USA, Inc. — Nationwide within the United States
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Recalling firm: Endo USA, Inc. — Nationwide within the United States
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Recalling firm: Endo USA, Inc. — Nationwide within the United States
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Recalling firm: Endo USA, Inc. — Nationwide within the United States
